GM-CSF |
|
Vaxjo ID |
52 |
|
Vaccine Adjuvant Name |
GM-CSF |
|
Alternative Names |
Granulocyte-macrophage colony stimulating factor |
|
Adjuvant VO ID |
VO_0001294
|
|
Description |
GM-CSF (Sargramostin) is a cytokine that activates mature granulocytes and macrophages (Vogel and Powell, 1995). |
|
Stage of Development |
Clinical Trial |
|
Components |
Granulocyte-macrophage colony stimulating factor; Sargramostim (yeast-derived rh-GM-CSF). GM-CSF is a glycoprotein of 127 amino acids. Recombinant human GM-CSF is produced in yeast and it differs from the natural human GM-CSF by substitution of Leu for Arg at position 23 (Vogel and Powell, 1995). |
|
Dosage |
GM-CSF (Sargramostin) shows a specific activity of 5.6 x 106 IU/mg as measured in a TF- I cell proliferation assay (Vogel and Powell, 1995). |
|
Function |
GM-CSF is able to activate mature granulocytes and monocyte/macrophages and dendritic cells, and may have utility as a co-adjuvant for vaccines and monclonal antibodies (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
